Though Moderna stock soared back then, in more recent times, the stock has stumbled. The company has seen vaccine sales ...

Moderna earns the No. 356 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences EXAS, Genmab ADR GMAB and Krystal Biotech KRYS are among the top 5 highly rated stocks ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.

Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast pipeline. Considering the full picture, now, with the stock down 80% over ...

On Monday, Moderna MRNA provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At the conference, the company lowered its previously issued sales ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced it would ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. This might not be enough to turn around the fortunes of the developer of go-to COVID-19 ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday. This ...

After donating $176 million in proceeds from his original stock options in 2023, Stéphane Bancel is taking a different path ...